Beppe Calò1,2, Ugo Falagario3, Francesca Sanguedolce4, Alessandro Veccia5, Marco Chirico3, Emanuel Carvalho-Diaz6, Paulo Mota6, Estêvão Lima6, Riccardo Autorino5, Giuseppe Carrieri3, Luigi Cormio3. 1. Department of Urology and Renal Transplantation, University of Foggia, Foggia, Italy. b.calo@hotmail.it. 2. Department of CUF Urology and Service of Urology, Hospital of Braga, Braga, Portugal. b.calo@hotmail.it. 3. Department of Urology and Renal Transplantation, University of Foggia, Foggia, Italy. 4. Department of Pathology, University of Foggia, Foggia, Italy. 5. Division of Urology, Department of Surgery, VCU Health, Richmond, VA, USA. 6. Department of CUF Urology and Service of Urology, Hospital of Braga, Braga, Portugal.
Abstract
PURPOSE: To determine the impact of time to restaging transurethral resection (Re-TUR) on recurrence-free survival (RFS), progression-free survival (PFS), and cancer specific survival (CSS) of patients with high-grade T1 bladder cancer (BC) treated with intravesical Bacillus Calmette-Guerin (BCG). MATERIALS AND PATIENTS: Our prospectively maintained NMIBC databases were queried to identify patients with high-grade T1 BC who underwent Re-TUR before receiving intravesical BCG treatment (induction + 1-year maintenance). Patients were divided into three groups based on time to Re-TUR (group A: ≤ 6 weeks; group B: > 6-12 weeks; group C: > 12-18 weeks). Kaplan-Meier plots were used to estimate differences in RFS, PFS, and CSS. Multivariate Cox regression analysis was used to assess the impact of time to Re-TUR on oncological outcomes. RESULTS: Overall, 269 high-grade T1 BC patients were eligible for the analysis. Nineteen (7.1%) had concomitant CIS. Median follow-up was 49.3 (IQR 25-65) months. Kaplan-Meier plots showed no differences in RFS, PFS, and CSS between the three groups. Multivariate Cox regression analysis showed that Group B had a slightly better RFS, while the other outcomes were not affected by time to Re-TUR. CONCLUSIONS: This is the first study testing the role of time to Re-TUR in a homogeneous population of patients with high-grade T1 BC who received complete BCG treatment. The study challenged the concept the sooner the Re-TUR the better, since time to Re-TUR did not significantly affect oncological outcomes.
PURPOSE: To determine the impact of time to restaging transurethral resection (Re-TUR) on recurrence-free survival (RFS), progression-free survival (PFS), and cancer specific survival (CSS) of patients with high-grade T1 bladder cancer (BC) treated with intravesical Bacillus Calmette-Guerin (BCG). MATERIALS AND PATIENTS: Our prospectively maintained NMIBC databases were queried to identify patients with high-grade T1 BC who underwent Re-TUR before receiving intravesical BCG treatment (induction + 1-year maintenance). Patients were divided into three groups based on time to Re-TUR (group A: ≤ 6 weeks; group B: > 6-12 weeks; group C: > 12-18 weeks). Kaplan-Meier plots were used to estimate differences in RFS, PFS, and CSS. Multivariate Cox regression analysis was used to assess the impact of time to Re-TUR on oncological outcomes. RESULTS: Overall, 269 high-grade T1 BCpatients were eligible for the analysis. Nineteen (7.1%) had concomitant CIS. Median follow-up was 49.3 (IQR 25-65) months. Kaplan-Meier plots showed no differences in RFS, PFS, and CSS between the three groups. Multivariate Cox regression analysis showed that Group B had a slightly better RFS, while the other outcomes were not affected by time to Re-TUR. CONCLUSIONS: This is the first study testing the role of time to Re-TUR in a homogeneous population of patients with high-grade T1 BC who received complete BCG treatment. The study challenged the concept the sooner the Re-TUR the better, since time to Re-TUR did not significantly affect oncological outcomes.
Entities:
Keywords:
High-grade; Non muscle-invasive bladder cancer; Oncological outcomes; Restaging transurethral resection; Time to re-TUR